Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03537794 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Characterizing Synaptic Density in Treatment Resistant Depression

Study acronym: TPET
StatusRecruiting
PhaseNot specified
Started2025-08-22
View on ClinicalTrials.gov ↗
The purpose of this study is to better understand how certain brain systems work in people with depression, especially in those whose symptoms have not improved with antidepressant treatments. The investigators are particularly interested in synaptic density, which helps to understand how different parts of the brain communicate with one another. Synaptic density levels have implications on overall brain function and cognition. By comparing brain function in people with treatment-resistant depression, people with treatment-responsive depression, and healthy controls, investigators hope to better understand why some individuals do not respond to antidepressants. This research may help guide the development of more effective treatments in the future.

Amendment history 3 changes detected by DataLookout

2026-09-02
critical
Primary endpoint(s) modified
WasDopamine potential
NowSynaptic Density
2026-09-02
critical
Primary completion pushed: 2027-12 → 2028-12
2026-09-02
minor
Completion pushed: 2028-12 → 2029-12
Trial Details
NCT Number NCT03537794
Lead Sponsor Unity Health Toronto
Collaborators: Centre for Addiction and Mental Health
Conditions Treatment Resistant Depression, Depression - Major Depressive Disorder
Enrollment 45 participants
Start Date 2025-08-22
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-09-15